Research
Hormonal
Personalized glycemic targets, adjusted for age, comorbidities, and hypoglycemia risk, improve patient outcomes by minimizing severe hypoglycemic events and enhancing quality of life, compared to rigid standard targets.
Work with your doctor to set a blood sugar target that is right for YOU. If you are older or have other health issues, a slightly higher blood sugar target might be safer to prevent dangerous lows. This personalized approach improves your quality of life and reduces hospital visits.
ModerateQualifiesMEDIUM confidence
The determination of glycemic targets considers a range of patient-specific factors, including age, duration of diabetes, presence of comorbidities (such as cardiovascular disease or kidney disease), and risk of hypoglycemia. Elderly individuals or those with notable comorbidities may require higher glycemic targets to minimize the risk of hypoglycemia. ... Customized glycemic control takes into consideration the potential risk of hypoglycemia, particularly in older individuals or those with significant concurrent medical conditions. The prevention of severe hypoglycemic events is associated with improved overall health and decreased hospitalizations
Why this rating
Review article citing guidelines and studies.
Source
Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine
Fnu Sugandh et al. · Cureus · 2023
DOI 10.7759/cureus.43697
narrative_reviewCited 258×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Personalized medicine, utilizing genetic screening and pharmacogenomics, improves diabetes management outcomes by tailoring treatment plans to individual genetic makeup, lifestyle, and health characteristics, thereby optimizing medication choices and reducing adverse reactions.Moderate
- Continuous Glucose Monitoring (CGM) and closed-loop 'artificial pancreas' systems significantly enhance glycemic control and reduce hypoglycemia risk by providing real-time data and automated insulin delivery.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →